Access cutting-edge chronic graft-versus-host disease treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.
Access chronic graft-versus-host disease specialists in Stanford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic graft-versus-host disease treatment provided free
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Sponsor: Incyte Corporation
Check if you qualify for this chronic graft-versus-host disease clinical trial in Stanford, CA
If you're searching for chronic graft-versus-host disease treatment options in Stanford, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.